Zentalis Pharmaceuticals Inc
Chart
Good to know: Investing in stocks tends to provide long-term positive returns, but it also involves risks. You can lose some or all of your investment. Past performance of this stock is not a reliable indicator of future results. Data from external providers has not been altered by Saxo. See full data disclaimer
About Zentalis Pharmaceuticals Inc
Zentalis Pharmaceuticals Inc is a clinical-stage biopharmaceutical company developing azenosertib (ZN-c3), a potentially first-in-class and best-in-class WEE1 inhibitor for patients with Cyclin E1-positive platinum-resistant ovarian cancer (Cyclin E1+ PROC). The Company manages its operations as a single segment for the purposes of assessing performance and making operating decisions.
/ 
Frequently asked questions
To buy Zentalis Pharmaceuticals Inc stock, open a Saxo account and fund it. With SaxoInvestor or SaxoTrader, you can easily search for Zentalis Pharmaceuticals Inc by name or ticker, choose the number of shares, and place your order.
The ticker symbol for Zentalis Pharmaceuticals Inc is ZNTL:xnas. You can use this code to quickly find the stock in Saxo’s platforms and track its price and performance.
Zentalis Pharmaceuticals Inc has its primary listing on NASDAQ. You can trade Zentalis Pharmaceuticals Inc with a Saxo account, alongside thousands of other stocks worldwide.
Yes, Zentalis Pharmaceuticals Inc is available to trade on SaxoInvestor and SaxoTraderGO. You can buy shares directly and include Zentalis Pharmaceuticals Inc as part of a broader investment portfolio. Explore our SaxoInvestor platform.
Learn more about investing and trading at Saxo’s educational content hub. Explore portfolio strategies, types of stocks, diversification, and valuation measures— so you can make more informed decisions when considering shares like Zentalis Pharmaceuticals Inc.